Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Boehringer, Eli Lilly to launch diabetes drug in India
Linagliptin, which is approved in the US, the European Union, Japan and other countries, including India, is an original research product of Boehringer. Lilly India managing director Melt
Linagliptin, which is approved in the US, the European Union, Japan and other countries, including India, is an original research product of Boehringer. Lilly India managing director Melt
The vaccine, which is approved for use in children aged six weeks through 18 months, is indicated to prevent invasive disease caused by Neisseria meningitidis serogroups C and
Potelligent Chok1SV which manufactures recombinant antibodies will be a host cell line. The technology will include BioWa’s glycosylation Potelligent Technology and Lonza’s GS Gene Expression System in the
As part of a complete discovery chemistry solution ChemDiv prepared complex and highly targeted medicinal chemical scaffolds, building blocks and templates. UCB spokesperson Benoit Kenda said, "UCB had
The study was conducted in 278 patients in Canada, Europe, and Australia with either Lu AE58054 (plus 10mg/day donepezil) or placebo (plus 10mg/day donepezil). Lundbeck Canada scientific affairs
As per the orphan drug status, the company will be able to market StrataGraft once it receives FDA clearance, and could get assistance from the FDA with guiding
Following this achievement, Summit will receive the final payment from a $1.5m funding agreement with US based DMD organizations. Summit chief executive officer Glyn Edwards said, "The funding
ABL is the biologics production facility for the five-year Science Moving TowArds Research Translation and Therapy (SMARTT) program led by Steven Idell of The University of Texas Health
RP103 gained standard review designation by FDA. The data from Raptor’s Phase 3 cystinosis trial of RP103, which met sole primary endpoint, was included in the NDA submission.
Under the agreement, Lilly will increase equity position in Novast by $20m with initial equity investment being made in Novast quite a few years ago through the Lilly